Congenital malformations, deformations and chromosomal abnormalities in patients with T2DM and TUD (Comparision between matched semaglutide vs other anti–diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)	HR (95% CI)
5,954	semaglutide	insulins	197 (3.3%)	223 (3.7%)	−0.4% (−1.1%, 0.2%)	0.81 (0.67−0.98)
5,955	semaglutide	metformin	199 (3.3%)	194 (3.3%)	0.1% (−0.6%, 0.7%)	1.01 (0.83−1.23)
4,831	semaglutide	DPP−4i	146 (3.0%)	164 (3.4%)	−0.4% (−1.1%, 0.4%)	0.87 (0.70−1.09)
5,325	semaglutide	SGLT2i	169 (3.2%)	186 (3.5%)	−0.3% (−1.0%, 0.4%)	0.88 (0.72−1.09)
5,388	semaglutide	SU	167 (3.1%)	175 (3.2%)	−0.1% (−0.8%, 0.5%)	0.93 (0.75−1.15)
2,659	semaglutide	TZD	71 (2.7%)	56 (2.1%)	0.6% (−0.3%, 1.4%)	1.23 (0.86−1.74)
5,337	semaglutide	other GLP−1RAs	173 (3.2%)	165 (3.1%)	0.2% (−0.5%, 0.8%)	1.03 (0.83−1.28)

Hazard Ratio (HR)

0.30 0.40 0.60 0.80 1.0 2.0 3.00